Self-microemulsifying drug-delivery system for improved oral bioavailability of pranlukast hemihydrate: Preparation and evaluation

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 167-176

  Baek, Myoung Ki ^a   Lee, Jong Hwa ^b   Cho, Young Ho ^c   Kim, Hak Hyung ^d   Lee, Gye Won ^c  

^a SK Biopharmaceuticals Co   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c Konyang University   (South Korea)

^d Pharvis Korea Pharm ^*  (South Korea)

Author keywords

Bioavailability; PLH; Pranlukast hemihydrates; SMEDDS; Solubility

Indexed keywords

BENZYL ALCOHOL; CARBOXYMETHYLCELLULOSE; CITRIC ACID TRIETHYL ESTER; CREMOPHOR; LABRASOL; LAUROGLYCOL FCC; MACROGOL 400; MYRISTIC ACID ISOPROPYL ESTER; OIL; PEGLICOL 5 OLEATE; POLYSORBATE 20; POLYSORBATE 80; PRANLUKAST; PROPYLENE GLYCOL; SORBITAN LAURATE; SURFACTANT; TRANSCUTOL P; TRIACETIN; TRIETHANOLAMINE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; FIRST PASS EFFECT; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PH MEASUREMENT; RAT; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIOAVAILABILITY; PLH; PRANLUKAST HEMIHYDRATES; SMEDDS; SOLUBILITY;

ANIMALS; CHROMONES; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; MALE; NANOPARTICLES; OILS; PARTICLE SIZE; RATS; SOLUBILITY; SURFACE-ACTIVE AGENTS;

RATTUS;

EID: 84872329977     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S37338     Document Type: Article

References (31)

1. Nakagawa N, Obata T, Kobayashi T, et al. In vivo pharmacologic profile of ONO-1078: a potent, selective and orally active peptide leukotriene (LT) antagonist. Jpn J Pharmacol. 1992;60(3):217-225.
2. Taniguchi Y, Tamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol. 1993;92(4):507-512.
3. Chono S, Takeda E, Seki T, Morimoto K. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin. Int J Pharm. 2008; 347(1-2):71-78.
4. Aungst BJ. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci. 1993;82(10):979-987.
5. Burcham DL, Maurin MB, Hausner EA, Huang SM. Improved oral bioavailability of the hypocholesterolemic DMP 565 in dogs following oral dosing in oil and glycol solutions. Biopharm Drug Dispos. 1997;18(8):737-742.
6. Serajuddin AT, Sheen PC, Mufson D, Bernstein DF, Augustine MA. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J Pharm Sci. 1988;77(5):414-417.
7. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm. 1998;167:155-164.
8. Craig DQM, Lievens HSR, Pitt KG, Storey DE. An investigation into the physico-chemical properties of self-emulsifying systems using low frequency dielectric spectroscopy, surface tension measurements and particle size analysis. Int J Pharm. 1993;96(1-3):147-155.
9. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm. 1994;106(1):15-23.
10. Wakerly MG, Pouton CW, Meakin BJ, Morton FS. Self-emulsification of vegetable oil-nonionic surfactant mixtures: a proposed mechanism of action. In: Scamehorn JF, editor. Phenomena in Mixed Surfactant Systems. Washington, DC: American Chemical Society; 1986:242-255.
11. Kararli TT, Needham TE, Griffin M, Schoenhard G, Ferro LJ, Alcorn L. Oral delivery of a renin inhibitor compound using emulsion formulations. Pharm Res. 1992;9(7):888-893.
12. Ghosh PK, Majithiya RJ, Umrethia ML, Murthy RS. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS PharmSci Tech. 2006;7(3):77.
13. Wu H, Lu C, Zhou A, Min Z, Zhang Y. Enhanced oral bioavailability of puerarin using microemulsion vehicle. Drug Dev Ind Pharm. 2009;35(2):138-144.
14. Myers RA, Stella VJ. Systemic bioavailability of penclomedine (NSC-338720) from oil-in-water emulsions administered intraduodenally to rats. Int J Pharm. 1992;78(1-3):217-226.
15. Schwendener RA, Schott H. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J Cancer Res Clin Oncol. 1996;122(12):723-726.
16. Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem. 2009;57(19):9141-9146.
17. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37(3-4):223-230.
18. Patel D, Sawant KK. Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev Ind Pharm. 2007;33(12):1318-1326.
19. Kang BK, Lee JS, Chon SK, et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 2004;274(1-2):65-73.
20. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561-1572.
21. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992;9(1):87-93.
22. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212(2):233-246.
23. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000;11 Suppl 2:S93-S98.
24. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm. 1995;114(1):103-110.
25. Welz R, Müller S. 5-(benzylmercapto)-1H-tetrazole as activator for 2′-O-TBDMS phosphoramidite building blocks in RNA synthesis. Tetrahedron Lett. 2002;43(5):795-797.
26. Ishido M, Shibakawa K, Nakao Y, Sawada M, Aishita H. Studies on the metabolic fate of leukotriene antagonist ONO-1078 (1): absorption, distribution and excretion after single administration to rats. Xenobio Metabol Dispos. 1993;8:2-26.
27. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000;50(1): 179-188.
28. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231-248.
29. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 1997;25(1):47-58.
30. Humberstone AJ, Charman WN. Lipid based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev. 1997;25(1): 103-128.
31. Dimitrijevic D, Shaw AJ, Florence AT. Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells. J Pharm Pharmacol. 2000;52(2):157-162.